Condition: Facioscapulohumeral Muscular Dystrophy · Sponsor: Newcastle University
Facioscapulohumeral Dystrophy (FSHD) is the third most common form of neuromuscular dystrophy worldwide with an estimated prevalence of one in 20,000. FSHD is an autosomal dominant genetic disease and is estimated to affect up to 3,000 people in the UK. The patient registry facilitates a questionnaire based research study to better characterise and understand the disease in the UK, and helps to identify potential participants eligible for clinical trials.
This description comes directly from the study's public registry record.
Registry Project Manager and Curator · 0191 2418640 · helen.walker2@newcastle.ac.uk
Registries Team · registries@ncl.ac.uk
Always discuss trial participation with your own doctor first.
| John Walton Muscular Dystrophy Research Centre | Newcastle upon Tyne, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04001582